PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26593212-9	2016	RESULTS: Co-administration of ETO with APE and pure AN decreased systemic exposure level of each compound in vivo.	Etoricoxib	30-33	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	39-42	
26593212-10	2016	The Cmax, AUC, t1/2 of ETO was decreased whereas Vd and CL of ETO was increased significantly after co-administration of ETO with pure AN and APE.	Etoricoxib	62-65	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	142-145	
26593212-10	2016	The Cmax, AUC, t1/2 of ETO was decreased whereas Vd and CL of ETO was increased significantly after co-administration of ETO with pure AN and APE.	Etoricoxib	62-65	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	142-145	
26593212-11	2016	In pharmacodynamic study, ETO alone and ETO+APE (10+200mg/kg) groups exhibited significant synergistic anti-arthritic activity as compared to groups ETO+AN, APE and AN alone.	Etoricoxib	40-44	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	157-160